DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
T-pharmacytes for Prostate Cancer Immunotherapy
Annual rept. 15 May 2011-14 May 2012
MASSACHUSETTS INST OF TECH CAMBRIDGE
Pagination or Media Count:
The goal of this project is to engineer T-cells for adoptive cell therapy of prostate cancer, by conjugating drug-loaded nanoparticles to therapeutic cells to enable targeted drug delivery to tumor sites and lymph nodes. Nanoparticles with cytokine proteins bound to their surfaces will be attached to the surface of T-cells the equivalent of delivering a drugloaded pill to each individual anti-tumor T-cell. These drug-carrying T-Pharmacytes will be continuously stimulated by the protein and carry these cytokine-loaded particles wherever they traffic in the body. We hypothesize that this strategy will provide a safe and effective means to augment adoptive cell therapy and allow the great promise of this immunotherapy to be realized for treatment of prostate cancer. The proposed studies will provide a preclinical test of this concept. If successful, this approach to enhancing an immunotherapy strategy already in clinical trials might be translated to patient treatment in a relatively short timespan.
APPROVED FOR PUBLIC RELEASE